Kang Taek Jin, Suga Hiroaki
Research Center for Advanced Science and Technology, Department of Chemistry and Biotechnology, Graduate School of Engineering, University of Tokyo, 113-8656 Tokyo, Japan.
Biochem Cell Biol. 2008 Apr;86(2):92-9. doi: 10.1139/O08-009.
It is well known that standard peptides, which comprise proteinogenic amino acids, can act as specific chemical probes to target proteins with high affinity. Despite this fact, a number of peptide drug leads have been abandoned because of their poor cell permeability and protease instability. On the other hand, nonstandard peptides isolated as natural products often exhibit remarkable pharmaco-behavior and stability in vivo. Although it is likely that numerous nonstandard therapeutic peptides capable of recognizing various targets could have been synthesized, enzymes for nonribosomal peptide syntheses are complex; therefore, it is difficult to engineer such modular enzymes to build nonstandard peptide libraries. Here we describe an emerging technology for the synthesis of nonstandard peptides that employs an integrated system of reconstituted cell-free translation and flexizymes. We summarize the historical background of this technology and discuss its current and future applications to the synthesis of nonstandard peptides and drug discovery.
众所周知,由蛋白质原性氨基酸组成的标准肽可以作为特异性化学探针,以高亲和力靶向蛋白质。尽管如此,许多肽类药物先导物由于细胞通透性差和蛋白酶不稳定性而被放弃。另一方面,作为天然产物分离得到的非标准肽在体内通常表现出显著的药理行为和稳定性。虽然有可能已经合成了许多能够识别各种靶点的非标准治疗性肽,但非核糖体肽合成酶很复杂;因此,很难设计这样的模块化酶来构建非标准肽库。在这里,我们描述了一种用于合成非标准肽的新兴技术,该技术采用了重组无细胞翻译和柔性酶的集成系统。我们总结了这项技术的历史背景,并讨论了其在非标准肽合成和药物发现中的当前及未来应用。